Drug Trial Radar · NCT05342623
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Last checked: Nov 19, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
286
Actual
Start
May 17, 2022
Primary completion
Feb 29, 2024
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind 12-week Treatment Period (Treatment Period 1), and the Long-term Extension Phase includes a double-blind Treatment Period (Treatment Period 2) of up to 52 weeks.
Conditions
- Chronic Kidney Diseases
- Pruritus
Interventions
Difelikefalin 1 mg Oral TabletDrug
Difelikefalin 1 mg medication taken orally 1 time/day
Placebo Oral TabletDrug
Placebo tablet taken orally 1 time/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects achieving at least a 4-point improvement from baseline with respect to the weekly mean of the daily 24-hour WI-NRS score at Week 12 of Treatment Period 1Time frame: Week 12 of Treatment Period 1
Locations
83 sites in 1 country. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Huntsville, Alabama
Cara Therapeutics Study Site
Phoenix, Arizona
Cara Therapeutics Study Site
Surprise, Arizona
Cara Therapeutics Study Site
Anaheim, California
Cara Therapeutics Study Site
Bakersfield, California
Cara Therapeutics Study Site
Beverly Hills, California
Cara Therapeutics Study Site
Chula Vista, California
Cara Therapeutics Study Site
El Centro, California
Cara Therapeutics Study Site
Garden Grove, California
Cara Therapeutics Study Site
La Mesa, California
Cara Therapeutics Study Site
Northridge, California
Cara Therapeutics Study Site
Ontario, California
Cara Therapeutics Study Site
Riverside, California
Cara Therapeutics Study Site
Santa Clara, California
Cara Therapeutics Study Site
South Gate, California
Cara Therapeutics Study Site
Tarzana, California
Cara Therapeutics Study Site
Vacaville, California
Cara Therapeutics Study Site
Valencia, California
Cara Therapeutics Study Site
Victorville, California
Cara Therapeutics Study Site
Arvada, Colorado
Cara Therapeutics Study Site
Denver, Colorado
Cara Therapeutics Study Site
New Haven, Connecticut
Cara Therapeutics Study Site
Atlantis, Florida
Cara Therapeutics Study Site
Cape Coral, Florida
Cara Therapeutics Study Site
Coral Gables, Florida
Cara Therapeutics Study Site
Fort Lauderdale, Florida
Cara Therapeutics Study Site
Hialeah, Florida
Cara Therapeutics Study Site
Miami, Florida
Cara Therapeutics Study Site
Miami, Florida
Cara Therapeutics Study Site
Orange City, Florida
Cara Therapeutics Study Site 2
Orlando, Florida
Cara Therapeutics Study Site
Orlando, Florida
Cara Therapeutics Study Site
Pembroke Pines, Florida
Cara Therapeutics Study Site
Riverview, Florida
Cara Therapeutics Study Site
Tampa, Florida
Cara Therapeutics Study Site
West Palm Beach, Florida
Cara Therapeutics Study Site
Albany, Georgia
Cara Therapeutics Study Site
East Point, Georgia
Cara Therapeutics Study Site
Nampa, Idaho
Cara Therapeutics Study Site
Huntley, Illinois
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.